Brain and Acute Leukemia, Cytoplasmic Gene Overexpression as a Prognostic Factor in Egyptian De novo Adult Acute Myeloid Leukemia Patients

Ahmed A Alnagar; Hesham M Al Hagrassy; Rania M Abdullah; Reham M El Shabrawy; Hossam Salah

doi:10.4103/ijmpo.ijmpo_215_20

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(06): 859-868
DOI: 10.4103/ijmpo.ijmpo_215_20

Original Article

Brain and Acute Leukemia, Cytoplasmic Gene Overexpression as a Prognostic Factor in Egyptian De novo Adult Acute Myeloid Leukemia Patients

Ahmed A Alnagar

Department of Medical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

,

Hesham M Al Hagrassy

Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

,

Rania M Abdullah

Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

,

Reham M El Shabrawy

Department of Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

,

Hossam Salah

Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

› Author Affiliations

Abstract

Background: Brain and acute leukemia, cytoplasmic (BAALC) gene is identified on chromosome 8q22.3 and implicated in normal hematopoiesis. BAALC gene overexpression is associated with poor outcome. Methods: We aimed to evaluate BAALC expression in de novo Egyptian acute myeloid leukemia (AML) cases and determine its prognostic value. We recruited 70 patients with de novo AML diagnosed and treated at clinical pathology and medical oncology departments, fulfilling inclusion criteria in our prospective study and evaluated BAALC expression level. Patients received induction therapy. The Institutional Review Board approved our study. Results: The mean age was 39.2 years ± 11.87, (18–60) with a male/female ratio of 3/2. The cutoff value of BAALC as a prognostic factor was 2.11 with sensitivity (86.1%), specificity (80%), positive predictive value (88.6%), and negative predictive value (76.2%.) (P < 0.001), 43 (61.4%) patients had high BAALC expression. Seventy-two percent of patients in the low BAALC group achieved complete remission (CR) compared to 42.1% in high BAALC expression group (P = 0.03). Patients with low BAALC (123.1 ± 4.9) had longer mean survival time than high BAALC group (45.85 ± 5.1) (P = 0.000). Conclusion: High-BAALC expression is an adverse prognostic factor, with a higher risk of relapse, lower CR rates, and lower survival in Egyptian de novo AML patients.

Keywords

Acute myeloid leukemia - adult - brain and acute leukemia - cytoplasmic - de novo - prognostic

Full Text

References

References
1 Vardiman JW, Arber DA, Brunning RD, Larson RA, Matutes E, Baumann I. et al. Therapy-related myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H. et al.editors WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. p. 127-9
2 Baldus CD, Thiede C, Soucek S, Bloomfield CD, Thiel E, Ehninger G. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: Prognostic implications. J Clin Oncol 2006; 24: 790-7
3 Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K. et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: A cancer and leukemia Group B (CALGB) study. Blood 2008; 111: 5371-9
4 Metzeler KH, Dufour A, Benthaus T, Hummel M, Sauerland MC, Heinecke A. et al. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: A comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol 2009; 27: 5031-8
5 Heuser M, Berg T, Kuchenbauer F, Lai CK, Park G, Fung S. et al. Functional role of BAALC in leukemogenesis. Leukemia 2012; 26: 532-6
6 Franzoni A, Passon N, Fabbro D, Tiribelli M, Damiani M, Damante G, Sarin YK. Histone post-translational modifications associated to BAALC expression in leukemic cells. Biochem Biophys Res Commun 2012; 417: 721-5
7 Weber S, Alpermann T, Dicker F, Jeromin S, Nadarajah N, Eder C. et al. BAALC expression: A suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia. Blood Cancer J 2014; 10: e173
8 Spanaki A, Perdikogianni C, Linardakis E, Kalmanti M. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia. Leuk Res 2007; 31: 639-42
9 Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G. et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A cancer and leukemia Group B study. Blood 2003; 102: 1613-8
10 Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M. et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005; 11: 1416-24
11 Rashed R, Kadry D, EL Taweel M, El Wahab NA, El TA.Hameed. Relation of BAALC and ERG gene expression with overall survival in acute myeloid leukemia cases. Asian Pac J Cancer Prev 2015; 16: 7875-82
12 Amirpour M, Ayatollahi H, Sheikhi M, Azarkerdar S, Shams SF. Evaluation of BAALC gene expression in normal cytogenetic acute myeloid leukemia patients in North-East of Iran. Med J Islam Repub Iran 2016; 30: 418
13 Zhou JD, Yang L, Zhang YY, Yang J, Wen XM, Guo H. et al. Overexpression of BAALC: Clinical significance in Chinese de novo acute myeloid leukemia. Med Oncol 2015; 32: 386
14 Soliman A, Aal AA, Afify R, Ibrahim N. BAALC and ERG expression in Egyptian patients with acute myeloid leukemia, relation to survival and response to treatment. Open Access Maced J Med Sci 2016; 4: 264-70
15 Qi X, Shen Y, Cen J, Chen H, Sun Y, Sheng H. et al. Up-regulation of BAALC gene may be an important alteration in AML-M2 patients with t (8; 21) translocation. J Cell Mol Med 2008; 12: 2301-4
16 Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB. et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: A cancer and leukemia Group B study. Blood 2010; 116: 5660-9
17 El-Sharnouby JA, Ahmed LM, Taha AM, Kamal O. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype. Egypt J Immunol 2008; 15: 131-43
18 Yahya RS, Sofan MA, Abdelmasseih HM, Saudy N, Sharaf-Eldein MA. et al. Prognostic implication of BAALC gene expression in adult acute myeloid leukemia. Clin Lab 2013; 59: 621-8
19 Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P. et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: A cancer and leukemia Group B study. J Clin Oncol 2009; 27: 3198-204
20 Eisfeld AK, Marcucci G, Liyanarachchi S, Döhner K, Schwind S, Maharry K. et al. Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia. Proc Natl Acad Sci USA 2012; 109: 6668-73